In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carving a Niche in Saliva-Based Diagnostics

Executive Summary

Given that most diagnostics deals are valued at one to two times sales, $150 million to $200 million may seem like a lot of money to pay for a company with less than $20 million in sales, but that's the value Epitope is placing on STC Technologies Inc. The stock deal aligns two companies who have been working together for some time, positioning them as a leader in the small but growing oral fluid and point-of-care diagnostics market.

You may also be interested in...



Rapid HIV Testing: How Big a Market, Really?

OraSure Technologies is first (with the exception of an outdated, complicated test sold by Abbott) to get coveted FDA approval for a rapid HIV diagnostic test, and it also won a hard-to-get CLIA waiver for the test after a one-day review by the Department of Health and Human Services; the waiver enables the test to be used in a much wider variety of non-laboratory settings. The company's opportunity looks huge, but the test's success is far from a sure bet.

Hansa Raises $121m To Fund Idefirix Launch

Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel